The development of type 2 diabetes at a young age disproportionately affects people of South Asian and African–Caribbean ethnicity, and obesity is associated with early-onset diabetes in all ethnic groups, indicates research presented at the virtual 56th EASD Annual Meeting.
A fully automated dual-hormone delivery system with pramlintide and faster-acting insulin aspart delivers overall glycemic control that is nearly as good as that achieved with a hybrid closed-loop system with the insulin only, report researchers at the virtual 56th EASD Annual Meeting.
The pilot MIDDAS study suggests that a 2-day per week very-low-calorie diet could be a viable alternative to a continuous diet for people with type 2 diabetes who struggle with this approach.
Randomized trial findings presented at the virtual 56th EASD Annual Meeting suggest that spinal cord stimulation may provide pain relief for people with painful diabetic neuropathy and an inadequate response to conventional treatment.
New immigrants to a Western country have an initially reduced risk for mortality if they are diagnosed with type 2 diabetes, but this survival advantage is reversed across generations of exposure to the local culture, researchers report.
Adding linagliptin to glimepiride treatment reduces some measures of glycemic variability and improves glycemic control in patients with HNF1A-MODY, indicate findings from the GLIMLINA trial.
Early-phase hyperglucagonemia in response to ingesting a meal is associated with postprandial glucose excursions in patients with type 1 diabetes, research suggests.
Researchers have demonstrated a sustained safety profile for intraperitoneal insulin infusion with an implantable pump in patients with type 1 diabetes and initially high glucose variability.
The VERTIS-CV investigators have presented further kidney outcomes data, supporting the renoprotective effects of the SGLT2 inhibitor medication class.
The results of the phase 2 LIBERATES trial suggest that flash glucose monitoring could reduce the time people with type 2 diabetes spend in hypoglycemia in the period following an acute coronary syndrome.
Less than half of women with gestational diabetes undergo a guideline-recommended test for type 2 diabetes within 12 weeks of delivery, show results presented in a poster at the virtual 56th EASD Annual Meeting.
Study findings presented at the virtual 56th EASD Annual Meeting indicate that polypharmacy is common among people with type 1 diabetes and is associated with an increased risk for adverse outcomes.
The novel oral insulin ORMD-0801 warrants further investigation as a treatment option for patients with inadequately controlled type 2 diabetes, indicate findings from a phase 2b trial presented at the virtual 56th EASD Annual Meeting.
A non-invasive imaging technique could make it possible to determine if people with longstanding type 1 diabetes have residual beta cells, researchers have reported at the virtual 56th EASD Annual Meeting.
Researchers report that being prescribed a loop diuretic is a marker of poor prognosis among people taking a SGLT2 inhibitor for type 2 diabetes, even if they do not have diagnosed heart failure.
Among people with type 1 diabetes using continuous glucose monitoring, shorter time in range is associated with an increased risk for microvascular complications, suggests an analysis of data from the RESCUE trial.
The increased risk for dementia associated with type 2 diabetes is strongest for vascular dementia, researchers have reported at the virtual 56th EASD Annual Meeting.
Screening of people aged 40 to 70 years using glycated hemoglobin would detect type 2 diabetes approximately 2 years earlier than when it is identified due to symptoms or incidental diagnosis, suggests an analysis of the UK Biobank.
Treatment with the IL-6 receptor inhibitor sarilumab is associated with a greater improvement in glycemic control than conventional DMARDs or adalimumab among patients with comorbid rheumatoid arthritis and diabetes, indicate findings from a post-hoc analysis.
Results from the D-LIFT trial suggest a reduction in liver fat content when dulaglutide, a glucagon-like peptide-1 receptor agonist, is added to standard care treatment in people with concurrent type 2 diabetes and non-alcoholic fatty liver disease.